Septerna Q1 revenue rises sharply helped by Novo Nordisk collaboration

Septerna

11/05/2026 21:52

Overview

US biotechnology firm's Q1 revenue rose sharply, beating analyst expectations

Company posted a narrower net loss compared to a year ago

Pipeline progress highlighted by positive SEP-631 Phase 1 data and SEP-479 trial initiation

Outlook

Company expects existing cash to fund operations at least into 2029

Result Drivers

COLLABORATION REVENUE - Q1 revenue increase driven by Novo Nordisk collaboration, including milestone payments and research services

PIPELINE ADVANCEMENT - Positive SEP-631 Phase 1 results and SEP-479 trial initiation highlighted as key portfolio progress

Company press release: ID:nGNXbC4djM

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$26.52 mln
$16.94 mln (8 Analysts)
Q1 EPS
-$0.19


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Septerna Inc is $43.00, about 80.1% above its May 8 closing price of $23.87

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)